Working together to find an effective treatment

As the COVID-19 pandemic continues to affect the world in unforeseen ways, in an effort to help researchers better understand this virus and further the development of effective treatments, Accencio® is undertaking a multiphase COVID-19/SARS-CoV-2 project where we are:

  • using our molecular landscaping technology to systematically identify clinical stage molecules which can potentially be retargeted immediately to the COVID-19 effort
  • providing our IP-GeoScape® molecular landscaping technology to researchers to help guide the creation of new molecules for use against COVID-19/SARS-CoV-2.

Thanks to the generous support of our initiative partners, access to all the information, visualizations and analysis generated as part of this project is to be provided free of charge to any/all researchers working in the area, specifically those searching for potential effective treatments.

Retargeting: discovering what’s already out there

Accencio® is currently applying our IP-GeoScape® technology and methods to biological targets including RNA polymerase inhibitors, viral protease inhibitors, and TLR7/8 antagonists to identify drugs that could be retargeted for use in COVID-19 patients. Our work involves identifying any relationships between the molecular structures of existing advanced clinical or marketed molecules and molecules claimed to/believed to interact with these validated COVID-19 biological targets, with the hope we might be able to offer some new ideas for effective COVID-19 treatments. Our focus areas include tackling viral replication, viral invasion and the cytokine storm. Results of this analysis will be provided free of charge through a combination of reports and webinars, all of which will be available via this page.

New molecule research: designing the effective treatments of the future

Accencio® is also currently applying our IP-GeoScape® technology and methods to support researchers looking for new molecular candidates for COVID-19 treatment by providing the relevant visualizations and analyses that we produce for direct independent use by researchers to help them find those potential new treatments in the most efficient and cost-effective way possible. Access to these visualizations and analyses will be provided free of charge through our new COVID-19 portal.